This study establishes rates of Guillain-Barré syndrome relapse among Pfizer-BioNTech BNT162b2 vaccine receivers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411356 | PMC |
| http://dx.doi.org/10.1001/jamaneurol.2021.3287 | DOI Listing |
Publication Analysis
Top Keywords
guillain-barré syndrome
8
rate recurrent
4
recurrent guillain-barré
4
syndrome mrna
4
mrna covid-19
4
covid-19 vaccine
4
vaccine bnt162b2
4
bnt162b2 study
4
study establishes
4
establishes rates
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!